Table S1 from Anti-Glypican-1 Antibody–drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1–Positive Cholangiocarcinoma
The exon skipping mutations of the receptor tyrosine kinase MET (METex14), leading to oncogenic MET, are increasingly reported in cancers, including in 3-4% of non-small cell lung cancer (NSCLC). MET
Ovarian cancer is one of the most lethal gynecological malignancies. Recurrence or acquired chemoresistance is the leading cause of ovarian cancer therapy failure. Overexpression of ATP-binding casset
Cholangiocarcinoma (CCA) is an epithelial malignancy with a dismal prognosis owing to limited treatment options. Here, we identified several compound candidates against CCA using a high-throughput dru
Small molecule binding data for protein Histone-arginine methyltransferase CARM1, Protein arginine N-methyltransferase 1, and Protein arginine N-methyltransferase 5, Uniprot O14744, Q86X55, and Q99873
Table S1: Nanostructured biomolecules approved or in clinical trials for cancer therapy [8]. Table S2: examples of pH-responsive medication delivery systems. Table S3. Nanocarriers
